Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Show more

1500 District Avenue, Burlington, MA, 01803, United States

Biotechnology

Healthcare

Market Cap

338.8M

52 Wk Range

$1.15 - $12.46

Previous Close

$7.83

Open

$7.75

Volume

377,654

Day Range

$7.67 - $8.80

Enterprise Value

326.6M

Cash

12.29M

Avg Qtr Burn

-2.916M

Insider Ownership

3.60%

Institutional Own.

68.19%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roluperidone (5-HT2A antagonist) Details Schizophrenia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.